Clinical Trial

Vagal Nerve Stimulation in Irritable Bowel Syndrome

Study acronym: RESILIENCE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2024 (before its estimated November 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks of treatment with a vagal nerve stimulator. The main objectives are: * To evaluate the clinical response, defined as a decrease of at least 50 points on the IBS-SSS questionnaire, of the treatment. * To ascertain whether the autonomic-vagal neurosignature, derived from pre-treatment registration of symptom profiles, autonomic responses and imaging of neuronal activity as a reaction to stress is able to predict therapeutic response to tVNS accurately. * To evaluate the effect of treatment on quality of life * To evaluate the effect of treatment on depression * To evaluate the effect of treatment on anxiety Participants will be asked to wear a wearable (Fitbit) and fill out a daily questionnaire for one week. Thereafter, a functional brain MRI will be performed. In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks at home. The comparison group will receive the same device but with a non-conducting electrode. Patients fill out weekly questionnaires during the treatment period and at follow-up moments 3 and 6 months after finishing the treatment period.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-16; most recent amendment 2024-08-01.
Status change: Not Yet Recruiting → Recruiting 2024-01-23
Trial Details
NCT Number NCT06090110
Lead Sponsor Maastricht University Medical Center
Conditions Irritable Bowel Syndrome
Enrollment 166 participants
Start Date 2023-12-01
Primary Completion 2025-11-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-02